These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 32933891)
1. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Mojtabavi H; Saghazadeh A; Rezaei N Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891 [TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770 [TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333 [TBL] [Abstract][Full Text] [Related]
4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial. Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441 [TBL] [Abstract][Full Text] [Related]
5. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313 [TBL] [Abstract][Full Text] [Related]
6. Treating COVID-19 with colchicine in community healthcare setting. Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478 [No Abstract] [Full Text] [Related]
7. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678 [TBL] [Abstract][Full Text] [Related]
8. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296 [TBL] [Abstract][Full Text] [Related]
9. IL-6: Relevance for immunopathology of SARS-CoV-2. Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C; J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677 [TBL] [Abstract][Full Text] [Related]
11. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241 [TBL] [Abstract][Full Text] [Related]
12. A plea for the pathogenic role of immune complexes in severe Covid-19. Vuitton DA; Vuitton L; Seillès E; Galanaud P Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273 [No Abstract] [Full Text] [Related]
13. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Nasonov E; Samsonov M Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514 [TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Moutsopoulos HM Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616 [No Abstract] [Full Text] [Related]
15. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ; Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597 [TBL] [Abstract][Full Text] [Related]
16. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638 [TBL] [Abstract][Full Text] [Related]
19. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]